Carisma Therapeutics Inc. (NASDAQ: CARM)

Introduction

Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company headquartered in Philadelphia, Pennsylvania. Founded in 2016, Carisma engineers monocytes and macrophages—key cells of the innate immune system—to develop immunotherapies for oncology, fibrosis, and autoimmune disorders. The company’s lead approach, CAR-Macrophages (CAR-M), aims to enhance anti-tumor immunity and tissue regeneration by equipping patient-derived immune cells with chimeric antigen receptors.

Corporate Structure

• Headquarters: Philadelphia, PA
• Founded: 2016
• Employees: 51–200 (LinkedIn)
• Key Leadership:
  • Steven Kelly, President & CEO
  • Michael Klichinsky, PharmD, PhD, Co-Founder & CSO
• Collaborations: University of Pennsylvania; Moderna Therapeutics

Recent Developments and News

• December 9, 2024 – Strategic Restructuring
  Carisma announced a pipeline reprioritization, discontinuing the CT-0525 anti-HER2 program and reducing headcount by 34% to focus on its in vivo macrophage engineering platform for fibrosis, oncology, and autoimmune indications.
• February 11, 2025 – Oppenheimer Healthcare Conference
  CEO Steven Kelly presented at the Oppenheimer 35th Annual Healthcare Life Sciences Conference.
• March 2025 – CT-0508 Publication
  The company’s first-in-human CAR-Macrophage trial in metastatic HER2+ solid tumors was published in Nature Medicine, reporting safety, evidence of tumor microenvironment remodeling, and preliminary anti-tumor activity.
• May 13, 2025 – Q1 2025 10-Q Filing
  Carisma reported cash and equivalents of $8.6 million as of March 31, 2025; research and development remained the largest expense category.
• Q4 2025 Outlook – CT-1119 Phase 1 Data
  CT-1119, an autologous anti-mesothelin CAR-Monocyte therapy for ovarian and pancreatic cancers, is expected to report initial data.

Financial and Strategic Analysis

Metric	Value
Stock price (2025-06-10)	$0.5904 (+160.32% YTD)
Daily trading volume	39,873,691 shares
52-week range	$0.1420 – $1.90
Market cap (intraday)	$33.8 million
Price/Sales (ttm)	0.47
Net income (ttm)	–$50.8 million
Cash and equivalents (mrq)	$8.6 million
Profit margin (ttm)	–254.3%
Return on assets (ttm)	–69.6%

• Liquidity: As of Q1 2025, Carisma reported $8.6 million in cash, indicating a need for additional funding to support ongoing research and development activities.
• Pipeline Focus: The strategic shift to in vivo macrophage platforms aims to lower manufacturing complexity compared to ex vivo approaches.
• Partnerships: The collaboration with Moderna encompasses in vivo CAR-M oncology and autoimmune research programs, including an anti-GPC3 therapy for hepatocellular carcinoma.
• Cost Management: The December 2024 restructuring is anticipated to reduce operating expenses while concentrating development efforts on selected programs.

Market Position and Industry Context

• Sector: Biotechnology research, cellular immunotherapies
• Competitive Landscape:
  • CAR-T therapies targeting hematologic cancers have gained approvals; CAR-M remains in earlier clinical stages, focused on solid tumors and fibrotic diseases.
  • Other myeloid-cell platforms are in preclinical or Phase 1 development, positioning Carisma among companies advancing macrophage-based therapies.
• Differentiators:
  • Proprietary platform engineering both monocytes and macrophages.
  • Collaborations with academic institutions and biopharmaceutical companies to broaden target indications.
• Challenges:
  • Establishing consistent clinical efficacy in solid tumors.
  • Navigating capital requirements amidst net losses and negative cash flow.

tl;dr

• On June 10, 2025, CARM closed at $0.5904, reflecting a 160.32% year-to-date increase on high volume.
• Carisma redirected resources on December 9, 2024, to its in vivo macrophage engineering platform, discontinuing CT-0525 and reducing staff by 34%.
• A Phase 1 CAR-Macrophage study (CT-0508) was published in Nature Medicine in March 2025, demonstrating safety and preliminary activity in HER2+ solid tumors.
• Next data milestone: CT-1119 anti-mesothelin CAR-Monocyte trial, with initial results anticipated in Q4 2025.
• As of Q1 2025, the cash position was $8.6 million, indicating a need for further financing to progress clinical programs.